Search
Arginine
go.drugbank.com/drugs/DB00125ApprovedInvestigationalNutraceuticalAn essential amino acid that is physiologically active in the L-form.
Mixtures: Aminosyn II in Dextrose, Aminosyn II in DextroseLinvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigationalFDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363] … [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the
DaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational[A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines. … _C. botulinum_ is known to produce toxins that can cause botulism in humans.
Respiratory Distress Syndrome
go.drugbank.com/conditions/DBCOND0027916Synonyms: Acute respiratory distress syndrome in adult or childLisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL). … [A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period.
Rosuvastatin
go.drugbank.com/drugs/DB01098ApprovedInvestigational[A181087, A181406] Rosuvastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [simvastatin], [fluvastatin], and [lovastatin] are considered first-line … found in clinical studies to result in a 45.8% to 54.6% decreases in LDL cholesterol levels, which is about three-fold more potent than [atorvastatin]'s effects on LDL cholesterol.
Categories: Drugs Used in DiabetesProducts: ROSUVASTATINA SPECIAL PRODUCT'S LINENuclear receptor subfamily 4 group A member 3
go.drugbank.com/bio_entities/BE0008998TargetHumansTranscriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. … Binds to NBRE motif in CCND1 promoter, resulting in the activation of the promoter and CCND1 transcription (By similarity).
Synonyms: Translocated in extraskeletal chondrosarcomaSerine/threonine-protein kinase Nek4
go.drugbank.com/bio_entities/BE0009498TargetHumansRequired for normal cell cycle arrest in response to double-stranded DNA damage
Synonyms: Never in mitosis A-related kinase 4Erdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigational[L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for
Ciltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigational[A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development … [A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744]